Neutralizing Antibodies against two HIV-1 Strains in Consecutively Collected Serum Samples: Cross Neutralization and Association to HIV-1 Related Disease

References

• Robert-Guroff M, Brom M, Gallo R C. HTLV-III neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 1985; 316: 72–74
   PubMed Web of Science ®Google Scholar
• Weiss R A, Clapham P R, Cheingsong-Popov R, Dalgleish A G, Carne C A, Weller I VD, Tedder R S. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 1985; 316: 69–72
   PubMed Web of Science ®Google Scholar
• Katzenstein D A, Vuicic L K, Latif A, Boulos R, Halsey N A, Quinn T C, Rastogi S C, Quinnan G V. Human immunodeficiency virus neutralizing antibodies in sera from North Americans and Africans. J Acquir Immune Defic Syndr 1990; 3: 810–816
   PubMedGoogle Scholar
• Arendrup M, Ulrich K, Nielsen J O, Lindhardt B Ø, Kusk P, Mathiesen L R, Pedersen C, Krogsgaard K. HIV neutralizing antibodies: Development and association with HIV related disease. Scand J Infect Dis 1989; 21: 19–26
   PubMed Web of Science ®Google Scholar
• Goudsmit J, Debouck C, Meloen R H, Smit L, Bakker M, Asher D M, Wolff A V, Gibbs C J, Gajdusek D C. Human immunodeficiency virus type 1 neutralization epitopes with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzces. Proc Natl Acad Sci USA 1988; 85: 4478–4482
   PubMed Web of Science ®Google Scholar
• Krohn K, Robey W G, Putney S, Arthur L, Nara P, Fishinger P, Gallo R C, Wong-Staal F, Ranki A. Specific cellular immuneresponse and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men. Proc Natl Acad Sci USA 1987; 84: 4994–4498
   PubMedGoogle Scholar
• Matthews T J, Langlois A J, Robey W G, Chang N T, Gallo R C, Fishinger P J, Bolonesi D P. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci USA 1986; 83: 9709–9713
   PubMed Web of Science ®Google Scholar
• Nara P L, Robey W G, Pyle S W, Hatc W C, Dunlop N M, Bess M, Kelliher J C, Arthur L O, Fishinger P J. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J Virol 1988; 62: 2622–2628
   PubMedGoogle Scholar
• Prince A M, Pascual D, Kosolapov L B, Kurokawa D, Baker L, Rubinstein P. Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human imunodeficiency virus. J Infect Dis 1987; 156: 268–272
   PubMed Web of Science ®Google Scholar
• Weber J N, Clapham P R, Weiss R A, Parker D, Roberts C, Duncan J, Weller I, Carne C, Tedder R S, Pinching A J, Cheingsong-Popov R. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis. Lancet 1987; 1: 119–122
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M, Giardina P J, Robey G, Jennings A M, Naugle C J, Akbar A N, Grady R W, Hilgartner M. HTLV-III neutralizing antibody development in transfusiondependent seropositive patients with B-thalassemia. J Immunol 1987; 138: 3731–3736
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M, Oleske J M, Connor E M, Epstein L G, Minnefor A B, Gallo R C. Relationship between HTLV-III neutralizing antibody and clinical status of pediatric acquired immunodeficiency syndrome (AIDS) and AIDS-related complex cases. Pediatr Res 1987; 21: 547–550
   PubMedGoogle Scholar
• Goudsmit J, Thiriart C, Smit L, Bruck C, Gibbs J. Temporal development of cross-neutralization between HTLV-IIIB and HTLV-IIIRF in experimentally infected chimpanzees. Vaccine 1988; 6: 229–232
   PubMedGoogle Scholar
• Pyle S W, Morein B, Bess J W, Åkerblom L, Nara P L, Nigida S M, Lerche N W, Robey W G, Fishinger P J, Arthur L O. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the external envelope glycoprotein (gpl2O). Vaccine 1989; 7: 465–473
   PubMedGoogle Scholar
• Lindhardt B, Ulrich K, Ryder L, Dickmeiss E, Sørensen H, Jørgensen J, Jersild C, Gunnet N. HTLV-III antibody testing in three Danish blood banks. Vox Sang 1986; 51: 9–14
   PubMed Web of Science ®Google Scholar
• Gaub J, Pedersen C, Poulsen A G, Mathiesen L R, Ulrich K, Lindhardt B, Faber V, Gerstoft J, Hofmann B, Lernestedt J O, Nielsen C M, Nielsen J O, Platz P. The effect of Foscarnet (Phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS 1987; 1: 27–33
   PubMed Web of Science ®Google Scholar
• Nielsen C M, Bygbjerg I C, Vestergaard B F. Detection of HIV antigens in eluates from whole blood collected on filterpaper. Lancet 1987; 1: 566–567
   PubMed Web of Science ®Google Scholar
• McDougal J S, Cort S P, Kennedy M S, Cabridilla C D, Feorino P M, Francis D P, Hicks D, Kalyanaraman V S, Martin L S. Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J Immunol Methods 1985; 76: 171–183
   PubMed Web of Science ®Google Scholar
• Reed L J, Muench H. A simple method of estimating fifty percent endpoint. Am J Hyg 1938; 27: 493–497
   Google Scholar
• Popovic M, Sarngadharan M G, Read E, Gallo R C. Detection, isolation, and continuous production of cytopathic retrovirus (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224: 497–500
   PubMed Web of Science ®Google Scholar
• Arendrup M, Lindhardt BØ, Krogsgaard K, Gaub J, Nielsen J O. Copenhagen Hepatitis Acuta Programme. Antibody to HIV in patients with acute hepatitis B in the period 1975–1984. Scand J Infect Dis 1987; 19: 167–172
   PubMed Web of Science ®Google Scholar
• Cheng-Mayer C, Homsy J, Evans L A, Levy J A. Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci USA 1988; 85: 2815–2819
   PubMedGoogle Scholar
• Weiss R A, Clapham P R, Weber J N, Dalgleish A G, Lasky L A, Berman P W. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 1986; 324: 572–575
   PubMed Web of Science ®Google Scholar
• Goudsmit J, Thiriart C, Smit L, Bruck C, Gibbs C J. Temporal development of cross neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees. Vaccine 1988; 6: 229–232
   PubMedGoogle Scholar